
Francesco Morescalchi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4096891/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Risk factors for postoperative eye pain in patients with non-painful eye disease undergoing pars plana vitrectomy: the Vltrectomy Pain (VIP) study. Minerva Anestesiologica, 2021, 87, 541-548. | 1.0 | 1 |
| 2 | Comparative assessment of intraocular inflammation following standard or heavy silicone oil tamponade: a prospective study. Acta Ophthalmologica, 2019, 97, e97-e102. | 1.1 | 27 |
| 3 | Systemic thromboembolic adverse events in patients treated with intravitreal anti-VECF drugs for neovascular age-related macular degeneration: an update. Expert Opinion on Drug Safety, 2019, 18, 803-815. | 2.4 | 13 |
| 4 | <p>Central Serous Chorioretinopathy: Pathogenesis and Management</p> . Clinical Ophthalmology, 2019, Volume 13, 2341-2352. | 1.8 | 57 |
| 5 | Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial. Clinical Ophthalmology, 2018, Volume 12, 587-591. | 1.8 | 4 |
| 6 | Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 1141-1148. | 1.9 | 27 |
| 7 | Controversies over the role of internal limiting membrane peeling during vitrectomy in macular hole surgery. Survey of Ophthalmology, 2017, 62, 58-69. | 4.0 | 46 |
| 8 | From the analysis of pharmacologic vitreolysis to the comprehension of ocriplasmin safety. Expert Opinion on Drug Safety, 2016, 15, 1267-1278. | 2.4 | 6 |
| 9 | Current Trends about Inner Limiting Membrane Peeling in Surgery for Epiretinal Membranes. Journal of Ophthalmology, 2015, 2015, 1-13. | 1.3 | 39 |
| 10 | Efficacy and vitreous levels of topical NSAIDs. Expert Opinion on Drug Delivery, 2015, 12, 1767-1782. | 5.0 | 18 |
| 11 | Heavy Silicone Oil and Intraocular Inflammation. BioMed Research International, 2014, 2014, 1-16. | 1.9 | 44 |
| 12 | Proliferative Vitreoretinopathy after Eye Injuries: An Overexpression of Growth Factors and Cytokines Leading to a Retinal Keloid. Mediators of Inflammation, 2013, 2013, 1-12. | 3.0 | 107 |
| 13 | Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy. Japanese Journal of Ophthalmology, 2012, 56, 608-612. | 1.9 | 48 |
| 14 | COVID-19 AdenoviralVector Vaccine and Central Retinal Vein Occlusion. Ocular Immunology and Inflammation, 0, , 1-3. | 1.8 | 13 |